Fosfomycin (Contepo) for Complicated Urinary Tract Infections
The Medical Letter on Drugs and Therapeutics · 06.07.2026 · 68 (1758) · 107-108
DOI: 10.58347/tml.2026.1758b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 06.07.2026.
Abstract (Originalsprache)
The FDA has approved an IV formulation of the epoxide antibacterial drug fosfomycin (Contepo – Meitheal) for treatment of adults with complicated urinary tract infections (cUTIs) caused by susceptible isolates of Escherichia coli or Klebsiella pneumoniae. Oral fosfomycin has been available in the US for years for treatment of uncomplicated urinary tract infections. IV fosfomycin has been available in other countries for decades.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Fosfomycin (Contepo) for Complicated Urinary Tract Infections. The Medical Letter on Drugs and Therapeutics, 68(1758), 107-108. https://doi.org/10.58347/tml.2026.1758b
Vancouver
Fosfomycin (Contepo) for Complicated Urinary Tract Infections. The Medical Letter on Drugs and Therapeutics. 2026;68(1758):107-108. doi:10.58347/tml.2026.1758b
BibTeX
@article{euvimed2026,
title = {Fosfomycin (Contepo) for Complicated Urinary Tract Infections},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1758},
pages = {107--108},
doi = {10.58347/tml.2026.1758b}
}
EUVIMED